Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences
02 sept. 2021 07h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will...
Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update
12 août 2021 07h30 HE
|
Prelude Therapeutics, Inc.
- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 – - Enrollment Ongoing in Multiple Expansion Cohorts in Phase 1 Trial of...
Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors
19 juil. 2021 07h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., July 19, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its...
Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update
11 mai 2021 07h30 HE
|
Prelude Therapeutics, Inc.
- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5...
Prelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference
05 mai 2021 07h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., May 05, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that...
Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update
16 mars 2021 08h00 HE
|
Prelude Therapeutics, Inc.
– Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set to Initiate Early in the Second Quarter – – Clinical Data Readouts Expected in 2H21 for Lead PRMT5...
Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences
03 mars 2021 07h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced...
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11 janv. 2021 18h20 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the...
Prelude Therapeutics Announces Pricing of Upsized Public Offering
07 janv. 2021 00h12 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision...
Prelude Therapeutics Announces Launch of Proposed Public Offering
04 janv. 2021 16h16 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that...